journal article·2024-08Open access

Lipid‐Polymer Nanoparticles Mediate Compartmentalized Delivery of Cas9 and sgRNA for Glioblastoma Vasculature and Immune Reprogramming

Huaqing Zhang, Wenxin Jiang, Tingting Song, Mingjie Song, Shengyu Liu, Jianping Zhou, Hao Cheng, Yang Ding

Advanced Science· Volume 11· Issue 32

Abstract

Abstract Hypervascularized glioblastoma is naturally sensitive to anti‐angiogenesis but suffers from low efficacy of transient vasculature normalization. In this study, a lipid‐polymer nanoparticle is synthesized to execute compartmentalized Cas9 and sgRNA delivery for a permanent vasculature editing strategy by knocking out the signal transducer and activator of transcription 3 (STAT3). The phenylboronic acid branched cationic polymer is designed to condense sgRNA electrostatically (inner compartment) and patch Cas9 coordinatively (outer compartment), followed by liposomal hybridization with angiopep‐2 decoration for blood–brain barrier (BBB) penetration. The lipid‐polymer nanoparticles can reach glioblastoma within 2 h post intravenous administration, and hypoxia in tumor cells triggers charge‐elimination and degradation of the cationic polymer for burst release of Cas9 and sgRNA, accompanied by instant Cas9 RNP assembly, yielding ≈50% STAT3 knockout. The downregulation of downstream vascular endothelial growth factor (VEGF) reprograms vasculature normalization to improve immune infiltration, collaborating with interleukin‐6 (IL‐6) and interleukin‐10 (IL‐10) reduction to develop anti‐glioblastoma responses. Collectively, the combinational assembly for compartmentalized Cas9/sgRNA delivery provides a potential solution in glioblastoma therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Extracellular vesicles in disease · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Natural Medicines Department of Pharmaceutics China Pharmaceutical University Nanjing 210009 China

State Key Laboratory of Functions and Applications of Medicinal Plants Guizhou Medical University Guiyang 550014 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province · Fundamental Research Funds for the Central Universities

References (18)

Show source-provided references
1. 10.1038/nature2172410.1038/nature21724 ↗
2. 10.1056/NEJMoa181604710.1056/NEJMoa1816047 ↗
3. 10.1038/s41591-020-1044-810.1038/s41591-020-1044-8 ↗
4. 10.1016/j.annonc.2020.04.01010.1016/j.annonc.2020.04.010 ↗
5. 10.1002/advs.20200292710.1002/advs.202002927 ↗
6. 10.1038/s41551-019-0485-110.1038/s41551-019-0485-1 ↗
7. 10.1038/s41551-020-0540-y10.1038/s41551-020-0540-y ↗
8. 10.1016/S1474-4422(08)70260-610.1016/S1474-4422(08)70260-6 ↗
9. 10.1016/j.biomaterials.2016.04.00810.1016/j.biomaterials.2016.04.008 ↗
10. 10.1021/acs.chemrev.6b0079910.1021/acs.chemrev.6b00799 ↗
11. 10.1016/j.addr.2021.11389110.1016/j.addr.2021.113891 ↗
12. 10.1038/s41593-019-0352-010.1038/s41593-019-0352-0 ↗
13. 10.1002/adma.20210464110.1002/adma.202104641 ↗
14. 10.1038/s41565-019-0539-210.1038/s41565-019-0539-2 ↗
15. 10.1038/nnano.2017.5410.1038/nnano.2017.54 ↗
16. 10.1002/advs.20210607210.1002/advs.202106072 ↗
17. 10.1016/j.bioactmat.2021.10.03910.1016/j.bioactmat.2021.10.039 ↗
18. 10.1002/adma.20190327710.1002/adma.201903277 ↗